Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Postive Bank Results This Earnings Season
by Sheraz Mian
Plenty of results are still to come, but the big banks are showing a notable improvement in their earnings power.
New Research Reports for Tesla, Exxon, JNJ & Others
by Sheraz Mian
Today's must-read reports are for Exxon Mobil (XOM), Johnson & Johnson (JNJ) and Tesla (TSLA).
Top 7 Research Reports for July 29, 2016
by Sheraz Mian
Today's must-read reports are for Amgen (AMGN), JPMorgan (JPM) and Mondelez (MDLZ).
4 Medical Instrument Stocks to Bet on This Earnings Season
by Zacks Equity Research
The medical instrument sector holds a lot of promise at this moment.
Rush in Medical Device Investments: Should You Buy These Stocks?
by Zacks Equity Research
Coming to the weakest links in the MedTech sector, we advise investors against names that offer little growth/opportunity in the near term.
Should You Buy Evolving Trends in Medical Devices?
by Zacks Equity Research
Given the U.S. government's pushback on tax-dodging, we expected some sloth to creep into the medical device space as far as M&As are concerned. But to our surprise, M&A activity worldwide has remained fairly stable.